Welch & Forbes LLC Reduces Holdings in Thermo Fisher Scientific Inc. $TMO

Welch & Forbes LLC decreased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.5% during the third quarter, HoldingsChannel reports. The fund owned 89,726 shares of the medical research company’s stock after selling 1,388 shares during the quarter. Welch & Forbes LLC’s holdings in Thermo Fisher Scientific were worth $43,519,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in TMO. Financial Management Network Inc. boosted its holdings in Thermo Fisher Scientific by 3.7% during the 3rd quarter. Financial Management Network Inc. now owns 511 shares of the medical research company’s stock valued at $248,000 after acquiring an additional 18 shares during the period. Bruce G. Allen Investments LLC lifted its position in shares of Thermo Fisher Scientific by 8.8% during the third quarter. Bruce G. Allen Investments LLC now owns 236 shares of the medical research company’s stock worth $114,000 after purchasing an additional 19 shares during the last quarter. Revolve Wealth Partners LLC boosted its position in Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after buying an additional 20 shares during the period. Elevation Wealth Partners LLC raised its position in Thermo Fisher Scientific by 35.1% during the 3rd quarter. Elevation Wealth Partners LLC now owns 77 shares of the medical research company’s stock valued at $37,000 after purchasing an additional 20 shares in the last quarter. Finally, S.A. Mason LLC lifted its stake in Thermo Fisher Scientific by 7.0% in the third quarter. S.A. Mason LLC now owns 319 shares of the medical research company’s stock worth $155,000 after acquiring an additional 21 shares during the period. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Thermo Fisher Scientific news, EVP Michael D. Shafer sold 10,725 shares of the business’s stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $600.00, for a total transaction of $6,435,000.00. Following the completion of the transaction, the executive vice president owned 18,731 shares in the company, valued at $11,238,600. The trade was a 36.41% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Frederick M. Lowery sold 6,912 shares of the firm’s stock in a transaction on Tuesday, December 2nd. The shares were sold at an average price of $581.94, for a total transaction of $4,022,369.28. Following the completion of the sale, the executive vice president owned 14,367 shares in the company, valued at $8,360,731.98. The trade was a 32.48% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 124,517 shares of company stock worth $72,363,568 over the last 90 days. 0.33% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

TMO has been the topic of several recent research reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Friday, January 9th. UBS Group reaffirmed a “neutral” rating and set a $615.00 price target on shares of Thermo Fisher Scientific in a research report on Friday. Leerink Partners upped their price objective on shares of Thermo Fisher Scientific from $545.00 to $580.00 and gave the company an “outperform” rating in a report on Wednesday, October 22nd. TD Cowen lowered their target price on Thermo Fisher Scientific from $696.00 to $683.00 and set a “buy” rating on the stock in a research note on Friday. Finally, Evercore ISI restated an “outperform” rating and set a $650.00 price target on shares of Thermo Fisher Scientific in a research report on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $633.68.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock opened at $578.20 on Friday. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $643.99. The firm has a market cap of $217.24 billion, a PE ratio of 32.59, a price-to-earnings-growth ratio of 3.89 and a beta of 0.91. The business’s fifty day simple moving average is $593.96 and its 200-day simple moving average is $537.07. The company has a quick ratio of 1.11, a current ratio of 1.89 and a debt-to-equity ratio of 0.67.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, January 29th. The medical research company reported $6.57 earnings per share for the quarter, beating the consensus estimate of $6.45 by $0.12. The company had revenue of $12.22 billion during the quarter, compared to the consensus estimate of $11.95 billion. Thermo Fisher Scientific had a return on equity of 16.92% and a net margin of 15.05%.Thermo Fisher Scientific’s revenue was up 7.2% compared to the same quarter last year. During the same period in the previous year, the company posted $6.10 EPS. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific declared that its board has initiated a stock buyback program on Thursday, November 6th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical research company to purchase up to 2.4% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s board believes its stock is undervalued.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, January 15th. Investors of record on Monday, December 15th were paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend was Monday, December 15th. Thermo Fisher Scientific’s payout ratio is presently 9.94%.

More Thermo Fisher Scientific News

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Q4 results beat expectations — Adjusted EPS $6.57 and revenue $12.21B (≈+7% YoY), driven by life-sciences tools and pharma demand; the print supports near-term organic growth narrative. Read More.
• Positive Sentiment: Analyst support remains — several firms reiterated buys/positive views and one bullish write-up called the pullback a buying opportunity, highlighting resilient margins and competitive positioning. Read More.
• Neutral Sentiment: 2026 guidance set in a narrow band — FY26 revenue guide $46.3B–$47.2B and EPS $24.22–$24.80, roughly around consensus but slightly below EPS midpoint; guidance implies modest 3%–4% organic growth and stabilizing demand. Read More.
• Negative Sentiment: Market reaction focused on cautious profit outlook and margin pressure — despite the beat, investors sold into the print due to conservative margin commentary and a guidance range that doesn’t accelerate growth significantly. Read More.
• Negative Sentiment: Analyst price-target trim — TD Cowen lowered its PT from $696 to $683 while keeping a Buy rating, signaling slightly reduced upside expectations even as coverage stays positive. Read More.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.